Press Release

  • Mining A $10,000 Quadrillion Asteroid

    Mining A $10,000 Quadrillion Asteroid

    LOS ANGELES, CA / ACCESSWIRE / February 1, 2021 / US Nuclear Corp. (OTCQB:UCLE)

    Bob Goldstein, CEO of US Nuclear Corp (OTC: UCLE) weighs in on asteroid mining, “Mining of rare and valuable metals from the asteroids has long been fantasized, but then disregarded as something that is in the distant future. However, recent breakthroughs in fusion energy could lead to a new generation of faster, more powerful spacecraft propulsion systems, precisely for the purpose of asteroid mining expeditions.”

    The mining of asteroids has long been viewed as a vast source of wealth consisting of rare earth elements and precious metals.  The short supply and high prices for these minerals have put us at odds with other countries, disrupting the supply chain of phones, computers, electric cars, and slowing our economic growth.  In fact, terrestrial reserves on Earth could be exhausted within the next few decades.

    (more…)

  • US Nuclear 2020 Year-End Shareholder Letter

    US Nuclear 2020 Year-End Shareholder Letter

    LOS ANGELES, CA / ACCESSWIRE / January 19, 2021 / US Nuclear Corp. (OTCQB:UCLE)

    Dear US Nuclear Corp. Shareholders,

    The very challenging year of 2020 has finally come to an end and our hearts and prayers go out to all COVID-19 victims, families, and friends. After such a tumultuous year for everyone, it is only appropriate to give you an update on US Nuclear’s operations and strategic goals moving forward.

    COVID-19 restrictions, precautions, and confusion caused a stall in US Nuclear Corp’s manufacturing process, which in turn, caused significantly lower revenues than our 2018 & 2019 levels. During this period, in order to protect our workers, we reduced the number of working staff, rotated work schedules, and hoarded our cash-on-hand. As with many other companies, US Nuclear has office personnel working partially or entirely at home, but we are manufacturers and much of our work is done in our Los Angeles and Cincinnati plants. We have been solely focused on returning our operations and sales to full normality, whether our employees are working in-office or from home. Towards the end of Q4 2020, bookings and quote requests were increasing, so we are expecting 2021 to be a cash-positive growth year.
    (more…)

  • New Policy Sets in Motion Nuclear Space Travel and Colonization

    New Policy Sets in Motion Nuclear Space Travel and Colonization

    LOS ANGELES, CA / ACCESSWIRE / January 11, 2021 / On December 16, 2020, the White House issued Space Policy Directive-6 (SPD-6), which outlines a national strategy for using space nuclear power and propulsion (SNPP) systems in a safe and effective manner. The new policy directive confirms the United States’ commitment to using SNPP systems and establishing nuclear power stations on the moon and beyond, which is good news for US Nuclear (OTCQB: UCLE) and partner MIFTI, who have designed and are testing thermonuclear fusion power generators.

    Scott Pace of the National Space Council, commented “Space nuclear power and propulsion is a fundamental enabling technology for American deep-space missions to Mars and beyond.  The United States intends to remain the leader among spacefaring nations, applying nuclear power technology safely, securely, and sustainably in space.” The key factor for enabling space travel is the new nuclear-powered propulsion systems, as traditional chemical-powered rocket fuels are hopelessly weak. DARPA, NASA, and the US Space Force have recently gotten serious and deployed the nuclear option. Why? Nuclear fuels and nuclear power systems, such as the highly-regarded MIFTI Z-pinch fusion reactor, can deliver 10,000,000 times the work (or energy) per payload pound than the chemical rocket fuels now used by Musk’s Space-X, Bezos’s Blue Origin, Branson’s Virgin Atlantic, as do Lockheed and Boeing.

    (more…)

  • US Space Force and NASA Looking to Privatize Nuclear Spacecraft Production

    US Space Force and NASA Looking to Privatize Nuclear Spacecraft Production

    LOS ANGELES, CA / ACCESSWIRE / December 7, 2020, / US Nuclear (OTCQB: UCLE) is the prime contractor to build MIFTI’s fusion generators, which could be used in the relatively near future to power the propulsion systems for space travel and provide plentiful, low-cost, clean energy for the earth and other planetary bases once our astronauts get to their destination, be it the moon, Mars, Saturn or beyond. Chemical-powered rockets opened the door to space travel, but are still far too slow and heavy even to travel to distant planets within our solar system, let alone travel to other stars. Accordingly, NASA is now looking for nuclear-powered rockets that can propel a space vessel at speeds close to the speed of light and thermonuclear power plants on the moon and Mars, as these are the next steps towards space exploration and colonization.

    (more…)

  • US Nuclear Corp. Announces Third Quarter 2020 Results

    US Nuclear Corp. Announces Third Quarter 2020 Results

    Los Angeles, CA. December 1, 2020 – US Nuclear Corp. (OTC: UCLE), a leading manufacturer of advanced radiation, chemical, and biological detection and UAV instrumentation, recently announced the financial results for the third quarter ended September 30, 2020.

    • Sales for the three months ended September 30, 2020, were $484,318 compared to $659,325 for the same period in 2019
    • Decrease in sales due to the impact of COVID-19 on the company and customers
    • Employee work hours reduced by half to help mitigate COVID-19 exposure and transmission, in addition to 14-day quarantine periods for employees who may have been exposed
    • Selling, general, and administrative expense were $1,021,507 compared to $1,729,246 for the same period in 2019, the decrease of $707,739 or 40.9% was due to careful money management and lower stock-based compensation
    • Stock-based compensation was $542,560 for the three months ended September 30, 2020, compared to $1,150,321 during the same period in 2019
    • Net loss of $850,386 due to impact of COVID-19
    • $309,632 in accounts receivable, $484,012 in cash, and $1,132,000 in backlogged orders

    Robert Goldstein, CEO of US Nuclear Corp., commented:

    “Despite many challenges imposed by COVID-19, we managed to have a safe and productive third quarter.  The temporary closure of one of our operating divisions reduced and staggered worker hours, and 14-day self-quarantine periods have fortunately proved successful in ensuring all our workers are safe and COVID-19 free, and while these factors have led to a temporary slowdown in sales and production, the safety of our employees and their families is our highest priority.
    (more…)

  • US Nuclear and Grapheton Brain Implants to Help Immobilized Patients

    US Nuclear and Grapheton Brain Implants to Help Immobilized Patients

    Los Angeles, CA.  November 2, 2020 – US Nuclear (OTC: UCLE) and Grapheton’s implantable bioelectronic sensors can be used to help treat millions of people worldwide suffering from mobility problems.  Neuroscientists stress there is a large unmet demand to develop implantable sensors and the artificial intelligence required to translate the brain signals into specific commands or actions. As many as 500,000 people worldwide suffer spinal cord injuries every year and approximately 1.7% of the U.S. population or 5.4 million people suffer from some form of paralysis. Furthermore, COVID-19 has caused an increase in the number of strokes, especially among younger individuals.
    (more…)

  • US Nuclear Secures Its Position at Bioelectronics Startup Grapheton

    US Nuclear Secures Its Position at Bioelectronics Startup Grapheton

    Los Angeles, CA.  October 19, 2020 – In addition to US Nuclear’s (OTC: UCLE) 40% stake in Grapheton, CEO Robert Goldstein has recently taken a seat on Grapheton’s board of directors and will now serve as Chief Strategy Officer. As Chief Strategy Officer for Grapheton, Robert Goldstein will help the business become a leader in the new field of bioelectronics and will cement the partnership between US Nuclear and Grapheton.

    Grapheton’s unique, patented bioelectronic implants lead the world in bio-compatibility and longevity. Bioelectronics is becoming popular among researchers and doctors, and the bioelectronics market is likely to experience tremendous growth in the near future. In recent years, there have been numerous breakthroughs using bioelectronics technology. A notable example, bioelectronic devices have been researched and used in clinical trials to treat rheumatoid arthritis and Crohn’s disease by electrically stimulating the vagus nerve to control inflammation and the immune response.

    Bioelectronics has the potential to become a vital branch of medical treatment. Medical care, in general, has made many advances in recent years, but there are a great many diseases, conditions, injuries, and remaining unmet patient needs that still need to be urgently addressed.
    (more…)

  • Tritium Monitor Market Soars Due to Construction of $20+ Billion ITER Fusion Energy Project

    Tritium Monitor Market Soars Due to Construction of $20+ Billion ITER Fusion Energy Project

    Los Angeles, CA.  October 6, 2020 – As the construction of the huge ITER tokamak grows towards completion, the tritium monitoring market is soaring. As the world leader in quality tritium monitoring instrumentation, US Nuclear’s (OTC: UCLE) Overhoff division is poised to capture a large portion of this business.

    The ITER fusion project seeks to develop a major new source of electric power to help supply the world’s fast-growing appetite for dependable, 24/7 electric power. Fusion is fueled by tritium and deuterium, which are both isotopes of hydrogen.  Tritium is in short supply and ITER will fully deplete the global inventory. ITER is a $20+ billion international scientific and engineering project jointly funded by the European UnionChinaIndiaJapanRussiaSouth Korea, and the United States.

    (more…)

  • US Nuclear Corp. Announces Second Quarter 2020 Results

    US Nuclear Corp. Announces Second Quarter 2020 Results

    Los Angeles, CA. September 24, 2020 – US Nuclear Corp. (OTC: UCLE), a leading manufacturer of advanced radiation, chemical, and biological detection and UAV instrumentation, recently announced the financial results for the second quarter ended June 30, 2020.

      • Sales for the three months ended June 30, 2020, were $302,201 compared to $1,530,523 for the same period in 2019
      • Decrease in sales due to the impact of COVID-19 on the company and customers
      • Overhoff operating branch was temporarily closed 3 months to allow employees to safely isolate themselves at home
      • Employee work hours reduced by half to help mitigate COVID-19 exposure and transmission
      • Selling, general, and administrative expense were $346,203 compared to $1,246,309 for the same period in 2019, the decrease of $900,106 or 72.2% was due to careful money management and lower stock-based compensation
      • Net loss of $145,117 due to impact of COVID-19
      • $841,000 available cash in the bank with approximately $850,000 of backlogged orders

    (more…)

  • Making Our COVID Survivors Whole Again By Solving Yet Another Desperate Shortage

    Making Our COVID Survivors Whole Again By Solving Yet Another Desperate Shortage

    Los Angeles, CA.  August 3, 2020 – US Nuclear Corp. (OTC: UCLE) aims to combat COVID-19 and help patients and survivors of the virus by working together with MIFTEC to produce an unlimited supply of domestic, low-cost medical isotopes.

    The IAEA is supporting more than 121 countries with RT-PCR equipment, which is used to rapidly detect COVID-19 in real-time by a nuclear-derived technique and is one of the most widely used and accurate lab methods. The isotope Co-60 is also being used to sterilize medical equipment, devices, and supplies for COVID-19 professionals to ensure they are safe for use.  Co-60 irradiation is one of the quickest and effective methods for sterilizing large volumes of this equipment.

    Medical isotopes and nuclear medicine are proving to be effective in sterilizing, detecting, and fighting COVID-19 and guiding successful treatment. In addition to damaging the patient’s lungs, this virus also attacks the heart, blood vessels, liver, intestines, brain, and nervous system. It causes blood clots and sometimes strokes or seizures. Unfortunately, as a result, many of our COVID-19 survivors will need serious medical help for months or years to come.

    Medical isotopes are being used for lung diagnostics, determining the extent of the patient’s disease, and mapping the COVID-19 proteins, while others are being researched as a possible treatment for combating severe COVID-19 cases. Medical isotopes are necessary for nuclear medicine diagnostic scans to guide the physician in treating our brave survivors.

    (more…)